Although the exact mechanisms remain insufficiently understood, the administration of angiotensin receptor–neprilysin inhibitors (ARNIs), a drug complex composed of a neprilysin inhibitor precursor and a non-peptide Ang II receptor blocker, has been shown to decrease the risk of death and hospitalizations in heart failure patients [133]. This evidence concerns the gene MME and heart failure.